Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Surgi-Vision Intercept

This article was originally published in The Gray Sheet

Executive Summary

Miniaturized MRI coil for prostate applications is launched at RSNA meeting following FDA 510(k) clearance. The coil will be distributed by GEMS, along with the previously cleared Intercept urethra and esophagus micro coils (1"The Gray Sheet" Oct. 30, 2000, p. 18). The firm also has a 510(k) pending for a vascular application of the Intercept. Clinical data presented at RSNA from an in vivo feasibility animal study sponsored by Surgi-Vision showed no complications observed using a 0.032 inch Intercept coil for intracoronary imaging, despite the coil staying in the target artery for 4-6 hours
Advertisement

Related Content

Surgi-Vision/GE Medical Will Market Internal MRI Coils In Early 2001
Surgi-Vision/GE Medical Will Market Internal MRI Coils In Early 2001
Advertisement
UsernamePublicRestriction

Register

MT014213

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel